Axsome Therapeutics Receives FDA Breakthrough Therapy Designation for AXS-05 for the Treatment of Alzheimer’s Disease Agitation
Designation offers potential for expedited development and reviewAxsome now granted two Breakthrough Therapy designations for AXS-05 for separate CNS indicationsNEW […]